IPP Bureau
India's First: Curapod wearable gets Class II nod for drug-free musculoskeletal pain relief
By IPP Bureau - December 24, 2025
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Ipsen acquires Simcere Zaiming’s innovative ADC SIM0613
By IPP Bureau - December 24, 2025
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
FDA nod to Boehringer Ingelheim’s JASCAYD for progressive pulmonary fibrosis in adults
By IPP Bureau - December 24, 2025
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
Gilead licenses Assembly Bio's investigational Herpes drugs after positive phase 1b data
By IPP Bureau - December 24, 2025
Under the 2023 collaboration agreement, Assembly Bio will receive $35 million for Gilead’s exercise of the HSV program option
Niagen Bioscience secures full ownership of key NAD+ patents in major IP move
By IPP Bureau - December 24, 2025
The portfolio includes foundational patents on the production, composition, and commercial use of NR
Hansa Biopharma submits FDA application for kidney transplant desensitization treatment
By IPP Bureau - December 24, 2025
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
Abbott’s Volt PFA System gets FDA nod
By IPP Bureau - December 24, 2025
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Enveda launches Phase 1 trial for first-in-class Oral IBD therapy
By IPP Bureau - December 24, 2025
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Asahi Kasei Pharma to move R&D hub to Shonan iPark in 2027
By IPP Bureau - December 24, 2025
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial
By IPP Bureau - December 24, 2025
Adverse events were consistent with valbenazine’s established safety profile
Novo Nordisk’s Wegovy pill approved in US as first oral GLP-1 for weight management
By IPP Bureau - December 23, 2025
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Bayer wins Japan nod for finerenone in broad heart failure population
By IPP Bureau - December 23, 2025
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
China approves first-in-class TGCT drug, marking global first for pimicotinib
By IPP Bureau - December 23, 2025
FDA grants breakthrough therapy designation to Enhertu for high-risk early breast cancer
By IPP Bureau - December 23, 2025
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
SRM Global Hospitals performs Tamil Nadu’s first TactiFlex radiofrequency ablation to save 80-yr-old patient
By IPP Bureau - December 23, 2025
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
